Skip to main content
OpenTrials
Completed

NCT Number: NCT06296511

The Influence of Acute Moderate-intensity Continuous Exercise on Appetite Regulation

A key area of obesity research has focused on the link between appetite, energy balance and weight control. Within this area, several appetite-related hormones and cellular cytokines have been identified as key signals influencing appetite and food intake. This includes the appetite-suppressing hormone oxyntomodulin (OXM) and a cellular stress-induced cytokine growth differentiation factor 15 (GDF-15).

The aims of this study are: (1) to investigate the effect of acute moderate-intensity continuous exercise on oxyntomodulin and GDF-15 concentrations; (2) to investigate whether exercise-induced changes in circulating OXM and GDF-15 concentrations are correlated with subjective appetite perceptions and subsequent energy intake.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Loughborough University

Loughborough, LE11 3TU, United Kingdom

About this study

Oxyntomodulin is thought to promote weight loss by suppressing appetite and energy intake and increasing energy expenditure. Acute exercise has been shown to increase the circulating concentration of satiety-related gut hormones, such as glucagon-like peptide-1 (GLP-1) and peptide YY (PYY). However, the effect of acute exercise on OXM concentrations in individuals with healthy weight has not been investigated.

GDF-15 is a cellular stress-induced cytokine which has recently been shown to suppress appetite. A few studies have explored the effect of acute exercise on GDF-15 concentrations but the findings are conflicting. Some studies have shown that acute exercise, which provides a transient physiological stress, increased GDF-15 concentrations, but other studies have not found any influence of exercise on GDF-15 concentrations. In addition, whether post-exercise appetite perceptions and subsequent energy intake are influenced by exercise-related changes in OXM or GDF-15 concentrations remains unknown.

To explore the impact of acute moderate-intensity continuous exercise on OXM and GDF-15 levels, alongside subjective appetite perceptions and subsequent energy intake, all participants in this crossover study engaged in both exercise and control trials, with a minimum one-week interval between each.

During the exercise trial, participants were asked to arrive at the lab at 8.30 am, having fasted overnight for 10 hours (except plain water). Participants were asked to rest in the lab for 30 minutes. During the resting period, a cannula was positioned in the participants' arm and a mask was fitted on the face in the last five minutes of the rest to allow for the collection of exhaled air during exercise. After the resting period, participants were asked to exercise at an intensity of 70 percent of their peak oxygen uptake for an hour before resting in the lab for a further 2.5 hours. Venous blood samples were collected before (0 minutes) and after (60, 90, 120, 150, 180, and 210 minutes) exercise and ad libitum energy intake was assessed 1 h after exercise completion. For the control trial, participants replicated all the procedures of the exercise trial except they rested for 1 h as the exercise counterpart.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Body mass index between 18.5-24.9 kg/m²;
  • Habitually consume three meals a day;
  • Able to run continuously for 1 hour;
  • Not currently dieting and weight stable for 3 months (< 3 kg change in weight);
  • No severe dislike or allergy to any of the study food;
  • Regular menstrual cycle in the past 6 months.

Exclusion criteria

  • Smokers (vaping is considered smoking in this study);
  • Individuals with medical conditions (e.g., diabetes, heart condition);
  • Individuals taking medications that may influence the study outcomes;
  • Individuals with clinically diagnosed eating disorders.

Treatment and study plan

Exercise

Behavioral

60 min of treadmill exercise performed at 70% of peak oxygen uptake.

Primary outcomes

  1. Oxyntomodulin

    Time frame: Blood samples were collected for oxyntomodulin measurements at 0 (baseline), 60, 90, 120, 150, 180, 210 minutes in each trial.

    (pmol/L)

  2. Growth Differentiation Factor 15

    Time frame: Blood samples were collected for GDF-15 measurements at 0 (baseline), 60, 90, 120, 150, 180, 210 minutes in each trial.

    (pg/mL)

Secondary outcomes

  1. Visual analogue score (VAS) for subjective appetite

    Time frame: VAS was measured at 0 (baseline), 60, 90, 120, 150, 180, 210 minutes in each trial.

    Subjective appetite sensations were assessed using 100mm visual analogue scales to measure four appetite constructs: 'hunger', 'fullness,' 'desire to eat' and 'expected food intake'.

  2. Energy intake

    Time frame: Ad libitum pasta meal provided at 120 minutes.

    (kcal); participants were required to self-serve from a large bowl containing an amount of pasta in excess of expected consumption for 30 minutes and were instructed to stop eating when they reach volitional satiation. The remaining food was weighed and subtracted from the known quantity initially presented to calculate ad libitum energy intake.

Sponsors and collaborators

Lead sponsor

Loughborough University

Other

Registry information

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Mar 6, 2024
Registry last updated
Mar 6, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.